Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,200,888
  • Shares Outstanding, K 106,544
  • Annual Sales, $ 8,497 M
  • Annual Income, $ 3,513 M
  • 60-Month Beta 0.20
  • Price/Sales 6.63
  • Price/Cash Flow 15.83
  • Price/Book 4.68
Trade REGN with:

Options Overview

Details
  • Implied Volatility 26.83%
  • Historical Volatility 18.54%
  • IV Percentile 7%
  • IV Rank 13.51%
  • IV High 48.55% on 10/05/20
  • IV Low 23.44% on 06/02/21
  • Put/Call Vol Ratio 0.65
  • Today's Volume 3,537
  • Volume Avg (30-Day) 2,107
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 52,400
  • Open Int (30-Day) 55,363

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 16.53
  • Number of Estimates 2
  • High Estimate 20.57
  • Low Estimate 12.50
  • Prior Year 6.29
  • Growth Rate Est. (year over year) +162.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
492.13 +6.39%
on 05/27/21
542.42 -3.47%
on 06/16/21
+6.96 (+1.35%)
since 05/14/21
3-Month
451.60 +15.94%
on 03/25/21
542.42 -3.47%
on 06/16/21
+41.41 (+8.59%)
since 03/16/21
52-Week
441.00 +18.73%
on 03/04/21
664.64 -21.22%
on 07/20/20
-69.32 (-11.69%)
since 06/16/20

Most Recent Stories

More News
Oracle, La-Z-Boy fall; General Motors, Rambus rise

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:

GM : 61.76 (+1.56%)
RMBS : 21.94 (+8.24%)
ELAN : 35.98 (+3.36%)
MX : 24.07 (-6.16%)
ORCL : 77.08 (-5.59%)
REGN : 523.58 (-0.74%)
LZB : 37.34 (-11.68%)
CCL : 29.28 (+2.34%)
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

REGN : 523.58 (-0.74%)
GSK : 40.66 (+0.22%)
BIIB : 391.31 (-1.20%)
VRTX : 187.49 (-0.78%)
NVAX : 176.24 (-5.79%)
SAGE : 54.88 (-6.67%)
ITOS : 26.03 (-1.40%)
Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail

Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.

REGN : 523.58 (-0.74%)
GSK : 40.66 (+0.22%)
RGEN : 190.14 (+0.26%)
VIR : 44.45 (+1.62%)
RAPT Reports Positive Data From Atopic Dermatitis Study

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

REGN : 523.58 (-0.74%)
SNY : 53.42 (-0.93%)
RGEN : 190.14 (+0.26%)
RAPT : 32.00 (-9.07%)
AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19

AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.

REGN : 523.58 (-0.74%)
AZN : 58.41 (-0.73%)
GSK : 40.66 (+0.22%)
LLY : 220.76 (-1.23%)
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2

/PRNewswire/ --

REGN : 523.58 (-0.74%)
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19

Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.

REGN : 523.58 (-0.74%)
LLY : 220.76 (-1.23%)
GILD : 67.33 (-1.12%)
COCP : 1.3000 (+0.78%)
Incyte (INCY) Faces Delay in Approval of Atopic Dermatitis Cream

Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.

REGN : 523.58 (-0.74%)
SNY : 53.42 (-0.93%)
NVS : 93.79 (-0.13%)
INCY : 83.12 (+0.43%)
Ophthalmic Drugs Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Ophthalmic Drugs Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the...

BAYRY : 16.0600 (-1.44%)
NVS : 93.79 (-0.13%)
PFE : 39.30 (-0.73%)
REGN : 523.58 (-0.74%)
VRX.TO : 30.80 (-3.33%)
Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it collaborated with...

TWST : 106.96 (-1.57%)
REGN : 523.58 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

3rd Resistance Point 556.77
2nd Resistance Point 549.59
1st Resistance Point 536.59
Last Price 523.58
1st Support Level 516.41
2nd Support Level 509.23
3rd Support Level 496.23

See More

52-Week High 664.64
Fibonacci 61.8% 579.21
Fibonacci 50% 552.82
Fibonacci 38.2% 526.43
Last Price 523.58
52-Week Low 441.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar